India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease
- Posted on July 17, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease
July 17 (Reuters) - Danish drugmaker Novo Nordisk said on Friday that India's drug regulator has approved its obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Here are a few details: • The Central Drugs Standard Control Organisation approved Wegovy's 2.4 mg semaglutide injection for the treatment of MASH,
